<DOC>
	<DOCNO>NCT00927901</DOCNO>
	<brief_summary>This study assess efficacy , safety , pharmacokinetics indacaterol salt ( maleate , xinafoate acetate ) patient asthma .</brief_summary>
	<brief_title>Efficacy , Safety , Tolerability , Pharmacokinetics Indacaterol Salts Patients With Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Maleic acid</mesh_term>
	<criteria>Nonsmoker male female adult patient age 1875 year inclusive , sign informed consent form prior initiation studyrelated procedure , include adjustment asthma medication prior screen . Patients asthma , receive daily treatment inhale corticosteroid . Patients force expiratory volume 1 second ( FEV1 ) screen ≥ 50 % predict normal value patient . Body mass index ( BMI ) must within range 1832 kg/m^2 ( inclusive ) . Able communicate well investigator comply requirement study . Exclusion criterion : A urine cotinine level great local laboratory low level quantification ( LOQ 500 ng/ml low ) . Patients severe asthma attack/exacerbation require hospitalization 6 month prior screen . Patients emergency room visit asthma attack/exacerbation within 6 week prior screen time screen predose day 1 study . Patients respiratory tract infection within 4 week prior screen time screen predose day 1 study . Patients require use ≥ 8 inhalation per day shortacting β2agonist salbutamol/albuterol ( 100 μg/90 μg salbutamol/albuterol meter dose inhaler [ MDI ] equivalent dose drypowder inhaler [ DPI ] ) 2 consecutive day screen randomization . Patients diagnose chronic obstructive pulmonary disease ( COPD ) define Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline ( 2008 ) . Participation clinical investigation within 4 week prior dose longer required local regulation . Previous participation study either investigational comparator drug exclude patient participation study . Significant illness . History immunocompromised , include positive human immunodeficiency virus ( HIV ) test result ( ELISA Western blot ) . A positive hepatitis B surface antigen ( HBsAg ) hepatitis C test result . Patients consider vulnerable per ICH GCP guideline . Patients history hypersensitivity indacaterol similar drug include untoward reaction sympathomimetic amine inhale medication component thereof . Treatments asthma allied condition : The following treatment use unless stabilize prior screening : antihistamine , inhale nasal cromolyn , inhale nasal corticosteroid , maintenance immunotherapy . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>QAB149</keyword>
	<keyword>asthma</keyword>
	<keyword>indacaterol salt ( acetate , maleate , xinafoate )</keyword>
	<keyword>orally inhale indacaterol salt</keyword>
	<keyword>persistent asthma</keyword>
</DOC>